Enoticumab
Enoticumab is an experimental drug that is currently under investigation for its potential use in the treatment of various types of cancer. It is a type of monoclonal antibody that targets the Notch receptor, a protein that plays a crucial role in cell development and differentiation.
Mechanism of Action[edit]
Enoticumab works by binding to the Notch receptor, thereby inhibiting its activation. The Notch signaling pathway is involved in the regulation of cell growth, differentiation, and apoptosis. Abnormal activation of this pathway has been implicated in the development and progression of several types of cancer, including leukemia, breast cancer, and lung cancer. By blocking the Notch receptor, enoticumab may help to slow the growth and spread of cancer cells.
Clinical Trials[edit]
Several clinical trials have been conducted to evaluate the safety and efficacy of enoticumab in patients with various types of cancer. These trials have provided valuable insights into the potential benefits and risks of this experimental drug. However, more research is needed to fully understand the therapeutic potential of enoticumab.
Side Effects[edit]
As with any drug, enoticumab may cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and vomiting. Less common side effects include diarrhea, constipation, and abdominal pain. Severe side effects, such as anemia, neutropenia, and thrombocytopenia, have also been reported. Patients should discuss the potential risks and benefits of enoticumab with their healthcare provider.
Future Directions[edit]
The future of enoticumab as a cancer treatment remains uncertain. While early clinical trials have shown promise, further research is needed to confirm these findings and to determine the optimal dosing and administration of this drug. Researchers are also investigating the potential use of enoticumab in combination with other cancer treatments.
| Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
 | |
|---|---|
 |
 |
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
This article is a medical stub. You can help WikiMD by expanding it!
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
